Ipsen (IPN.PA)

Executive Summary

Ipsen is a global biopharmaceutical company headquartered in Paris, France, with a market valuation of $12.77 billion USD. The company focuses on oncology, rare diseases, and neuroscience, developing innovative small molecule and biologic therapeutics for high unmet medical needs. Ipsen's commercial portfolio includes established products like Somatuline (lanreotide) for neuroendocrine tumors and acromegaly, and Dysport (abobotulinumtoxinA) for various indications. In recent years, Ipsen has strengthened its pipeline through acquisitions and approvals, notably the FDA approval of Iqirvo (elafibranor) for primary biliary cholangitis (PBC) in 2024. The company continues to invest in high-potential programs, including elafibranor for other hepatic conditions and palovarotene for fibrodysplasia ossificans progressiva (FOP). With a diversified portfolio and a disciplined R&D strategy, Ipsen is well-positioned for sustained growth in the near term.

Upcoming Catalysts (preview)

• Q3 2026EU regulatory decision for Iqirvo (elafibranor) in primary biliary cholangitis80% success
• Q4 2026Phase 3 top-line data readout for elafibranor in primary sclerosing cholangitis60% success